Yahoo
NSE - Free Realtime Quote INR

Indegene Limited (INDGN.NS)

619.90 +33.10 (+5.65%)
As of 2:14:52 PM GMT+5:30. Market Open.
Chart Range Bar
Loading chart for INDGN.NS
  • Previous Close 586.80
  • Open 624.50
  • Bid 619.50 x --
  • Ask 619.90 x --
  • Day's Range 615.10 - 638.00
  • 52 Week Range 414.00 - 638.00
  • Volume 1,688,343
  • Avg. Volume 638,915
  • Market Cap (intraday) 149.287B
  • Beta (5Y Monthly) 0.75
  • PE Ratio (TTM) 36.46
  • EPS (TTM) 17.00
  • Earnings Date --
  • Forward Dividend & Yield 2.25 (0.38%)
  • Ex-Dividend Date Jul 31, 2026
  • 1y Target Est 671.62

Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, North America, and internationally. It operates through Enterprise Medical Solutions, Enterprise Commercial Solutions, and Other segments. The company provides AI-embedded commercialization services for biopharmaceutical, emerging biotech, and medical devices companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms, as well as provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Further, it engages in the professional, and scientific and technical activities. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.

www.indegene.com

4,687

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

INDGN.NS
19.63%
S&P BSE SENSEX (^BSESN)
11.87%

1-Year Return

INDGN.NS
15.43%
S&P BSE SENSEX (^BSESN)
10.52%

3-Year Return

INDGN.NS
5.36%
S&P BSE SENSEX (^BSESN)
17.21%

5-Year Return

INDGN.NS
5.36%
S&P BSE SENSEX (^BSESN)
25.12%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY27
Revenue 11.22B
Earnings 1.12B
Profit Margin 10.01%

Q3

FY26

Q4

FY26

Q1

FY27

Q2

FY27

0
2B
4B
6B
8B
10B
8.0%
9.0%
10.0%

Analyst Insights

View More

Analyst Price Targets

570.00 Low
671.62 Average
619.90 Current
735.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.95%

  • Return on Assets (ttm)

    7.79%

  • Return on Equity (ttm)

    13.21%

  • Revenue (ttm)

    41.31B

  • Net Income Avi to Common (ttm)

    4.11B

  • Diluted EPS (ttm)

    17.00

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    12.56B

  • Total Debt/Equity (mrq)

    4.68%

  • Levered Free Cash Flow (ttm)

    9.75B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: